Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension
GSK announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris® (ambrisentan) to include its use in combination treatment for patients with pulmonary arterial hypertension (PAH). Volibris is indicated for treatment of PAH in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment.
- Read more about Clinical trial purely for academic research may be approved by the IEC instead of DCGI
Health Ministry decided that academic clinical research may be approved by the Institutional Ethics Committee, however, in the case of new drug is being evaluated or a new use of an existing drug is being evaluated, then approval of DCG(I) is required at 70th meet of DTAB.
- Read more about New drug that may cure baldness found
In some good news for people with receding hairlines, scientists have identified new drugs that could stimulate rapid and robust hair growth, offering a potential cure for baldness. The drugs inhibit a family of enzymes inside hair follicles that are suspended in a resting state, restoring hair growth, researchers said. In experiments with mouse and human hair follicles, Angela M Christiano from Columbia University Medical Center and colleagues found that drugs that inhibit the Janus kinase (JAK) family of enzymes promote rapid and robust hair growth when directly applied to the skin.
- Read more about Lab-grown functional human liver cells to aid treatment
Researchers have developed a new approach to rapidly expand the number of human liver cells in the laboratory without losing their unique metabolic function.
- Read more about New gene map shows cancer's weak link
Scientists have mapped out the genes that keep our cells alive, thereby revealing which genes are crucial in diseases like cancer.
- Read more about Government moves on organ transplant facilities
Union Health Minister J.P. Nadda on Friday said the government has taken some decisive initiatives to accelerate the number of organ donations and to open organ transplant facilities at all major government hospitals.

[adsense:336x280:8701650588]
- Read more about High-potency cannabis kills white matter in brain
Smoking high-potency cannabis can damage a crucial part of the brain responsible for communication between the two brain hemispheres, researchers warn.
- Read more about FDA approves Portrazza to treat advanced squamous non-small cell lung cancer
The U.S. Food and Drug Administration approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Portrazza is marketed by Eli Lilly and Company, based in Indianapolis, Indiana.
- Read more about FDA approves first seasonal influenza vaccine containing an adjuvant
The U.S. Food and Drug Administration approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.
- Read more about Elocta, a new drug co-marketed by Sobi and Biogen, has been approved in the European Union for treatment of Haemophilia A
The injectable drug has been hailed as the first meaningful advance in treating haemophilia A in 20 years, and looks set to be a big earner for the partners. Elocta – a recombinant factor VIII Fc fusion protein (rFVIIIFc) – is already launched in the US, Canada and Australia under the Eloctate trade name, and is forecast to reach peak sales of $1.5 billion thanks to patient-friendly dosing that increases the time between injections.